Wegovy approved for fatty liver disease
CDSCO approves Wegovy for non-cirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis
- CDSCO approved Wegovy for a new indication in fatty liver disease.
- Wegovy contains semaglutide injection 2.4 mg and is described as a GLP-1 receptor agonist.
- Non-cirrhotic metabolic dysfunction associated steatohepatitis (MASH) develops because excess fat accumulates in the liver and causes chronic inflammation and liver damage.
What happened
India’s drugs regulator, the Central Drugs Standard Control Organization (CDSCO), approved Wegovy (semaglutide injection 2.4 mg) for a new indication: fatty liver disease. Novo Nordisk said the approval covers non-cirrhotic metabolic dysfunction associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, together with a reduced-calorie diet and increased physical activity.
Background and earlier position
UPSC may ask about the therapeutic class, the disease definition, and the role of CDSCO in drug regulation. The issue also opens a Mains discussion on non-communicable disease management, obesity-linked metabolic disorders, and the balance between innovation, affordability, and access.
